Spinbionic Spółka z Ograniczoną Odpowiedzialnością (KRS 0001072497, NIP 9721346644) is a Polish company, headquartered in Poznań, Wielkopolskie voivodeship. SPINBIONIC operates in: Research and experimental development on biotechnology (PKD 72.11.Z). Industry: Research and development. The company has been listed in the National Court Register since November 30, 2023. SPINBIONIC's most recently reported net revenue was 211.3 K PLN for 2024.
No arrears identified in the analyzed sources
No arrears or bankruptcy proceedings identified in the analyzed sources.
Business profile - Spinbionic
Identity
- Name
- Spinbionic Spółka z Ograniczoną Odpowiedzialnością
- Legal form
- SPÓŁKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ
- Founded
- November 30, 2023
- Registry status as of
- December 3, 2025
- Latest entry
- July 4, 2025
- Founding act
- 05.10.2023 R., KANCELARIA NOTARIALNA MIKOŁAJ SIENNICKI - NOTARIUSZ, REP. A NR 11.692/2023
Articles of association history (1)
- October 5, 2023: 05.10.2023 R., KANCELARIA NOTARIALNA MIKOŁAJ SIENNICKI - NOTARIUSZ, REP. A NR 11.692/2023
Activities
Main activity
72.11.ZResearch and experimental development on biotechnology
Other activities
General codes (divisions and groups)
General codes indicate a PKD division or group without a specific subclass.
Address and contact
- Address
- UL. WSZECHNICY PIASTOWSKIEJ, 3, 1/21, 61-614, POZNAŃ, POLSKA
- Voivodeship
- WIELKOPOLSKIE
- District
- POZNAŃ
- Not disclosed in the registry
- Website
- Not disclosed in the registry
- E-delivery address
- AE:PL-17748-67191-GWFBU-23
- Coordinates
- 52.4079, 16.9335approx.
Risk and payment profile - Spinbionic
Credibility rating
69 / 100
Good credibility
Insolvency risk
Very low
Low threat
Closure risk
2
/ 100
Risk comparison - scale 0 (safe) → 100 (critical)
Organizational stability signals
No instability signals - ownership, management, PKD codes and company name remain relatively stable.
Shareholder changes
0
0/2 yrs
Board changes
0
0/2 yrs
PKD changes
0
0/2 yrs
Name changes
0
0/2 yrs
Data from 2 years of registry activity.
Difference between risk models
Closure - probability of ceasing operations (operational continuity). Insolvency - probability of formal bankruptcy / restructuring. The models use different data - results can diverge significantly when balance-sheet data is incomplete.
Operational status - Spinbionic
Founded
November 30, 2023
2 years in operation
Legal form
SPÓŁKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ
Registry: RejP
Headquarters
POZNAŃ
WIELKOPOLSKIE
Primary PKD
72.11.Z
Research and experimental development on biotechnology
Share capital
5.0 K PLN
96 shares total
Shareholders
3
shareholders
Board
3 people
Filed years
1 year
2024
Registry entries
7
latest: July 4, 2025
Revenue
211.3 K PLN
2024
Net profit
76.5 K PLN
2024
Assets
99.1 K PLN
2024
Equity
81.5 K PLN
2024
Valuation
402.1 K PLN
Low confidence
Low confidence
Companies in the same location
Public procurement
Trademarks
Reviews
Rate business credibility - Spinbionic.
No ratings
Related articles
News
Bioceltix in the final EMA dialogue phase: BCX-CM-J could become Europe's first veterinary cell-therapy drug for dogs
Wrocław-based Bioceltix S.A. (KRS 0000744521) entered Q2 2026 in the final EMA dialogue phase regarding BCX-CM-J - Europe's first veterinary cell-therapy drug from mesenchymal stem cells for dogs with osteoarthritis. Responses to the final EMA questions are due in May 2026; the CVMP recommendation and marketing authorisation are possible in Q3/Q4 2026. Pre-commercial biotech: 2024 closed with a PLN 14.9 m loss on zero revenue; cash of PLN 33.6 m at year-end. Trigon DM maintained a buy rating with a price target of PLN 127.2.
News
Captor Therapeutics: PLN 36 m of cash at 30 September 2025, runway to mid-2026 - clinical data versus the cash clock
Wrocław-based Captor Therapeutics S.A. (KRS 0000756383) - a pre-commercial biotech specialising in TPD (Targeted Protein Degradation) - closed Q3 2025 with PLN 36 m of cash and grants securing financing to mid-2026. CT-01 (hepatocellular carcinoma) entered Phase I - the first patient dosed at Barcelona Clinic Liver Cancer. CT-03 (MCL-1 degrader) nearing clinical entry. Without a new R&D partnership or equity issuance in 2026, the company will need additional financing.
